Novo Nordisk A/S (NVO) Announces FDA Approval of Three New Indications for Sogroya

Novo Nordisk A/S (NYSE:NVO) is one of the best cheap stocks under $50 to buy right now. Novo Nordisk A/S (NYSE:NVO) announced ...

FDA approves Novo Nordisk's Sogroya(R) as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

FDA Approves Novo Nordisk's Growth Disorder Treatment For New Populations

Novo Nordisk received approval from the Food and Drug Administration for three new indications of Sogroya, a growth hormone.